Information Provided By:
Fly News Breaks for December 19, 2017
Dec 19, 2017 | 06:59 EDT
After evaluating the company's strategic options, including the sale of its U.K. business, monetizing its real estate, and a leveraged buyout, Jefferies analyst Brian Tanquilut believes "meaningful value" could be realized in Acadia Healthcare, even absent any near-term improvement in fundamentals. A divestiture of the U.K. business or a sale-leaseback could push Acadia shares to $46, Tanquilut tells investors in a research note. In a leveraged buyout, Acadia should command greater than $48 per share, the analyst contends. He views the company as a viable LBO candidate and keeps a Buy rating on the shares with a $42 price target.
News For ACHC From the Last 2 Days
There are no results for your query ACHC
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.